|
|
???tair.name??? >
???browser.page.title.author???
|
"vogel a"???jsp.browse.items-by-author.description???
Showing items 1-10 of 35 (4 Page(s) Totally)
1 2 3 4 > >>
View [10|25|50] records per page
| 國家衛生研究院 |
2025-05-15 |
Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study
|
Oh, DY;He, AR;Qin, S;Chen, LT;Okusaka, T;Kim, JW;Suksombooncharoen, T;Lee, MA;Kitano, M;Burris, HA;Bouattour, M;Tanasanvimon, S;Zaucha, R;Avallone, A;Cundom, J;Kuzko, A;Wang, J;Xynos, I;Vogel, A;Valle, JW |
| 國家衛生研究院 |
2024-12-19 |
Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer[Erratum:ESMO Open. 2024 Aug 06;9(8):Article number 103647.]
|
Chen, LT;Vogel, A;Hsu, C;Chen, MH;Fang, W;Pangarsa, EA;Sharma, A;Ikeda, M;Park, JO;Tan, CK;Regala, E;Tai, D;Tanasanvimon, S;Charoentum, C;Chee, CE;Lui, A;Sow, J;Oh, DY;Ueno, M;Ramaswamy, A;Jeo, WS;Zhou, J;Curigliano, G;Yoshino, T;Bai, LY;Pentheroudakis, G;Chiang, NJ;Cervantes, A;Chen, JS;Ducreux, M |
| 國家衛生研究院 |
2024-08-06 |
Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer
|
Chen, LT;Vogel, A;Hsu, C;Chen, MH;Fang, W;Pangarsa, EA;Sharma, A;Ikeda, M;Park, JO;Tan, CK;Regala, E;Tai, D;Tanasanvimon, S;Charoentum, C;Chee, CE;Lui, A;Sow, J;Oh, DY;Ueno, M;Ramaswamy, A;Jeo, WS;Zhou, J;Curigliano, G;Yoshino, T;Bai, LY;Pentheroudakis, G;Chiang, NJ;Cervantes, A;Chen, JS;Ducreux, M |
| 國家衛生研究院 |
2024-08 |
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): Updated overall survival from a randomised phase 3 study
|
Oh, DY;He, AR;Bouattour, M;Okusaka, T;Qin, S;Chen, LT;Kitano, M;Lee, CK;Kim, JW;Chen, MH;Suksombooncharoen, T;Ikeda, M;Lee, MA;Chen, JS;Potemski, P;Burris, HA, 3rd;Ostwal, V;Tanasanvimon, S;Morizane, C;Zaucha, RE;McNamara, MG;Avallone, A;Cundom, JE;Breder, V;Tan, B;Shimizu, S;Tougeron, D;Evesque, L;Petrova, M;Zhen, DB;Gillmore, R;Gupta, VG;Dayyani, F;Park, JO;Buchschacher, GL, Jr.;Rey, F;Kim, H;Wang, J;Morgan, C;Rokutanda, N;Żotkiewicz, M;Vogel, A;Valle, JW |
| 國家衛生研究院 |
2023-09-25 |
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer
|
Oh, DY;He, AR;Qin, SK;Chen, LT;Okusaka, T;Vogel, A;Kim, JW;Suksombooncharoen, T;Lee, MA;Kitano, M;Burris, H;Bouattour, M;Tanasanvimon, S;McNamara, MG;Zaucha, R;Avallone, A;Tan, BJM;Cundom, J;Lee, CK;Takahashi, H;Ikeda, M;Chen, JS;Wang, JL;Makowsky, M;Rokutanda, N;Zotkiewicz, M;Kurland, JF;Cohen, G;Valle, JW |
| 國家衛生研究院 |
2023-03-31 |
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) [Erratum:Annals of Oncology. 2022 Nov;33(Suppl. 9):S1462
|
Oh, D;He, AR;Qin, S;Chen, L;Okusaka, T;Vogel, A;Kim, JW;Suksombooncharoen, T;Lee, MA;Kitano, M;Burris, HA;Bouattour, M;Tanasa, S;Zaucha, RE;Avallone, A;Cundom, JE;Rokutanda, N;Żotkiewicz, M;Cohen, G;Valle, JW |
| 國立成功大學 |
2023 |
Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
|
Xie, E.;Yeo, Yeo Y.H.;Scheiner, B.;Zhang, Y.;Hiraoka, A.;Tantai, X.;Fessas, P.;De, Castro T.;D'Alessio, Alessio A.;Fulgenzi, C.A.M.;Xu, S.;Tsai, H.-M.;Kambhampati, S.;Wang, Wang W.;Keenan, B.P.;Gao, X.;Xing, Z.;Pinter, M.;Lin, Y.-J.;Guo, Z.;Vogel, A.;Tanaka, Tanaka T.;Kuo, H.-Y.;Kelley, R.K.;Kudo, M.;Yang, J.D.;Pinato, D.J.;Ji, F. |
| 國立成功大學 |
2023 |
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer
|
Oh, D.-Y.;He, A.R.;Qin, S.;Chen, L.-T.;Okusaka, T.;Vogel, A.;Kim, J.W.;Suksombooncharoen, T.;Lee, M.A.;Kitano, M.;Burris, H.;Bouattour, M.;Tanasanvimon, S.;McNamara, McNamara M.G.;Zaucha, R.;Avallone, Avallone A.;Tan, B.;Cundom, J.;Lee, C.-K.;Takahashi, H.;Ikeda, M.;Chen, J.-S.;Wang, J.;Makowsky, Makowsky M.;Rokutanda, N.;Żotkiewicz, M.;Kurland, J.F.;Cohen, G.;Valle, J.W. |
| 國家衛生研究院 |
2022-11 |
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)
|
Oh, DY;He, AR;Qin, S;Chen, LT;Okusaka, T;Vogel, A;Kim, JW;Lee, T;Lee, MA;Kitano, M;Burris, HA;Bouattour, M;Tanasanvimon, S;Zaucha, RE;Avallone, A;Cundom, JE;Rokutanda, N;Zotkiewicz, M;Cohen, G;Valle, JW |
| 國家衛生研究院 |
2022-09 |
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)
|
Oh, DY;He, AR;Qin, S;Chen, LT;Okusaka, T;Vogel, A;Kim, JW;Suksombooncharoen, T;Lee, MA;Kitano, M;Burris, HA;Bouattour, M;Tanasanvimon, S;Zaucha, RE;Avallone, A;Cundom, JE;Rokutanda, N;Watras, M;Cohen, G;Valle, JW |
Showing items 1-10 of 35 (4 Page(s) Totally)
1 2 3 4 > >>
View [10|25|50] records per page
|
